Director, Pricing & Contracting

Director, Pricing & Contracting Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early-stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7). Nav1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof-of-concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. We are seeking a Director, Pricing and Contracting to join our Market Access team. This role will be responsible for U.S. pricing and contracting strategy to support optimal market access, reimbursement, and financial performance for Xenon’s portfolio. This role will lead the development of contracting strategies with national/regional payer organizations, PBMs, and government payer segments as well as pricing strategy, gross-to-net modeling, and payer contracting strategies that support both product launch planning and lifecycle management. This individual will work closely with the payer field team to support contract negotiations and ensure pricing and contracting decisions align with overall market access strategies and company financial objectives. This role will collaborate cross-functionally with Finance, Legal, Compliance, Medical Affairs, and Commercial leadership to evaluate pricing scenarios, inform access strategy decisions, and support the successful commercialization of Xenon products. This role reports to the Senior Director of Market Access Strategy and Operations and is based out of Boston, MA, USA, in our Needham office. The level of the position will be commensurate with the candidate’s education and industry experience. Hybrid positions require a minimum of two onsite days per week. RESPONSIBILITIES: - Lead the development and execution of U.S. pricing strategy, including launch price recommendations and lifecycle pricing management - Design and implement payer contracting strategies, including rebate structures and contracting frameworks with pharmacy benefit managers (PBMs), national payer organizations, and regional health plans - Support contract negotiations and ensu ... (truncated, view full listing at source)